## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.2% below STRENGTH zone (4.0-10.0%); PEG 1.51 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (48% of avg), momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($73.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. New research highlights Hologic’s AI tools for mammography**
- Source: DOTmed | 20251201T190442 | Bullish | Relevance: 99%
- New clinical data presented at RSNA 2025 highlights Hologic's AI-based mammography technologies, 3DQuorum and Genius AI Detection. A study on 3DQuorum showed it maintains cancer detection rates while improving workflow efficiency, potentially addressing staffing shortages. Another ongoing study on Genius AI Detection indicated higher cancer detection but also increased false positives, alongside Hologic showcasing Envision mammography and hosting educational events.

**2. RSNA 2025: Hologic Shares New Evidence on AI-Powered Mammography Solutions**
- Source: Medical Product Outsourcing | 20251201T161841 | Bullish | Relevance: 99%
- Hologic presented new data at RSNA 2025 showcasing the potential of its AI-powered mammography solutions, including 3DQuorum imaging technology and Genius AI Detection. Studies demonstrated that 3DQuorum can streamline radiologists' workflows without compromising cancer detection rates, while Genius AI Detection performed similarly to radiologists in identifying cancers. Hologic emphasizes its commitment to advancing breast health technologies and using AI to enhance efficiency and effectiveness in cancer screening.

**3. Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It**
- Source: www.sharewise.com | 20251201T140003 | Somewhat-Bullish | Relevance: 98%
- This article analyzes Hologic, Inc. (HOLX) as a trending stock, focusing on key factors such as earnings estimate revisions, revenue growth forecasts, and valuation. It highlights Hologic's recent stock performance, Zacks Rank #3 (Hold) rating, and projections for future earnings and revenue. The analysis suggests that while the stock is trending due to search interest, its near-term performance is expected to be in line with the broader market.

**4. Breast Health Performance Likely to Aid Hologic's Q1 Earnings**
- Source: MSN | 20251202T063751 | Somewhat-Bullish | Relevance: 98%
- Hologic's strong Breast Health segment performance is expected to be a key driver for its fiscal first-quarter 2024 earnings. Despite potential challenges in the Diagnostics and Medical Aesthetics divisions, growth in Breast Health, particularly from the Panther platform, is anticipated to support overall revenue. The company is set to release its Q1 2024 results on January 31, 2024.

**5. New research highlights Hologic’s AI tools for mammography**
- Source: DOTmed | 20251201T190447 | Somewhat-Bullish | Relevance: 97%
- New clinical data presented at RSNA 2025 highlights Hologic’s AI-based mammography technologies, including 3DQuorum and Genius AI Detection solutions. A retrospective study on 3DQuorum found it maintained cancer detection rates while improving workflow efficiency. Another study on Genius AI Detection showed higher cancer detection but reduced specificity, indicating an ongoing evaluation.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $76 | $69 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.27M) |
| Sells | 25 ($6.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $6.6M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.51 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.5x). Analyst sentiment positive (1 raises, avg +10%). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 0.70 |
| 52W Range | $51.90 - $77.32 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.51 |
| Forward P/E | 15.0 |
| Current P/E | 16.4 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.2% to -1.2% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). Volume at 48% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.21% (CS: 45) | Neutral |
| RSI_14 | 68.5 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 1.149x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.82
- **Stop Loss:** $73.90 (1.2% risk)
- **Target:** $75.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1086
- **Position Value:** $81,254.52
- **Portfolio %:** 81.25%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*